Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given an average recommendation of “Hold” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $3.20.

A number of brokerages have weighed in on GOSS. Weiss Ratings reissued a “sell (e+)” rating on shares of Gossamer Bio in a research report on Friday, August 14th. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a report on Monday, July 27th. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target for the company in a research note on Tuesday, July 28th.

Gossamer Bio Trading Up 16.9%

Gossamer Bio stock opened at $0.20 on Wednesday. The firm has a market cap of $48.00 million, a price-to-earnings ratio of -0.29 and a beta of 2.04. The stock has a fifty day simple moving average of $0.17 and a two-hundred day simple moving average of $0.44. Gossamer Bio has a 12 month low of $0.11 and a 12 month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $9.24 million for the quarter, compared to the consensus estimate of $3.63 million. On average, equities research analysts forecast that Gossamer Bio will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently added to or reduced their stakes in GOSS. Kalehua Capital Management LLC bought a new position in shares of Gossamer Bio in the 1st quarter worth approximately $3,363,000. Corient Private Wealth LLC grew its position in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after buying an additional 3,825,879 shares during the period. GSA Capital Partners LLP purchased a new stake in Gossamer Bio during the second quarter valued at approximately $2,467,000. ARCH Venture Management LLC purchased a new stake in Gossamer Bio during the second quarter valued at approximately $1,326,004,000. Finally, SG Americas Securities LLC raised its position in Gossamer Bio by 73.4% in the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock worth $42,000 after acquiring an additional 54,439 shares during the period. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.